Clinical Report: Reevaluation of the Immune Profile in Scalp Psoriasis

Overview

This study identifies a distinct immune profile in scalp psoriasis (SP) patients, highlighting a Th1/Th17/IL-12/IL-23-dominant molecular signature.

Background

Scalp psoriasis is a prevalent form of psoriasis that significantly impacts patients' quality of life. Understanding the unique immune mechanisms underlying SP is crucial for developing targeted therapies. This study utilizes Olink proteomics to explore the inflammatory biomarkers associated with SP, providing insights into its pathophysiology.

Data Highlights

Key Findings

• 28 differentially expressed proteins (DEPs) identified in lesional SP compared to healthy controls.
• SP exhibits a Th1/Th17/IL-12/IL-23-dominant molecular signature.
• Significantly reduced levels of IL-4 and IL-5 in SP patients.
• Negative correlation between IL-4 and IL-5 levels and scalp-specific Investigator’s Global Assessment (ss-IGA) scores.
• GO clustering and KEGG pathway analyses reveal interrelationships among cytokines, chemokines, and their receptors in SP.

Clinical Implications

The findings suggest that targeting the Th1/Th17 pathway may be beneficial in treating scalp psoriasis. Additionally, monitoring Th2 cytokines could provide insights into disease severity and treatment response.

Conclusion

This study enhances the understanding of the immunological pathogenesis of scalp psoriasis and highlights the need for targeted therapeutic strategies.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse
2. Clinical Rheumatology, 2020 -- Timely Identification of Psoriatic Arthritis in Patients with Psoriasis: Insights from Clinical Practice
3. Frontiers in Medicine, 2026 -- Single-cell landscape of immune remodeling in alopecia areata suggests MIF + fibroblasts and their potential ligand-receptor crosstalk with dendritic cells
4. Frontiers in Immunology — Integrative plasma proteomics and myeloid- interferon profiling reveal an AI-validated vascular- endothelial stress signature distinguishing SLE flare from remission in an Indian cohort a discovery – phase study
5. NPF Issues Position Statement on Psoriasis Severity and Access to Care
6. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial - PubMed
7. Systematic review and network meta-analysis of biologics and small molecules for scalp psoriasis - PubMed
8. Longitudinal plasma proteomics identifies diagnostic and response-associated inflammatory and immune biomarkers in psoriasis following secukinumab therapy